Follow the Pundits

Tag: high conviction investing

Ron Baron amid Tesla and SpaceX imagery illustrating Baron Capital’s patient growth strategy, concentrated bets and long-term compounding.

🚀 The House of Elon & Patience: Inside Ron Baron’s Compounding Engine 🪐🎢

Ron Baron built an investing career around a deceptively difficult idea: find exceptional businesses, back exceptional leaders and wait. We examine Baron Partners Fund, its huge SpaceX and Tesla exposure, long-term compounding record—and the concentration risk that comes with conviction.

 

Read entire article

Tags: Baron Capital, Baron Partners Fund, BaronCapital, BPTIX, buy and hold, compounding, Elon Musk, featured-hedge-funds, FUNanc1al, fund analysis, FunFund Index, growth investing, GrowthInvesting, high conviction investing, hub-hedge, investment strategy, long-term investing, LongTermInvesting, mutual funds, MutualFunds, portfolio concentration, private markets, Ron Baron, RonBaron, SpaceX, stock market, Tesla, ValueInvesting
Golden fortress in a rugged mountain landscape with glowing DNA strands and a lone investor silhouette, symbolizing John Paulson’s high-conviction bets on gold and biotech

🏔️ John Paulson 2025: From "Short of the Century" to the "Long of the Decade"

John Paulson is back. After years under the radar, the legendary investor posted a 58% return in 2025—driven by high-conviction bets in biotech, gold, and strategic minerals. This is not diversification. This is precision investing.

Read entire article

Tags: 13f analysis, event driven investing, EventDrivenInvesting, featured-hedge-funds, funanc1al, gold stocks, GoldInvesting, hedge funds, high conviction investing, hub-hedge, john paulson, JohnPaulson, macro investing, madrigal pharmaceuticals, MDGL, mining stocks, MiningStocks, PaulsonAndCo, perpetua resources, portfolio strategy, stock market insights, StockMarket2026, THM
A glowing gold bar with rising stock charts and biotech symbols, representing John Paulson’s concentrated investment strategy in gold and healthcare.

John Paulson’s $5,000 Gold Bet: Genius or Gamble? 🚀

A hyper-concentrated portfolio, a $5,000 gold target, and massive biotech bets—John Paulson is back with one of the boldest strategies in markets today.

Read entire article

Tags: 13F Filings, Bausch Health, Biotech Stocks, Biotech Stocks 2026, featured-hedge-funds, FUNanc1al stocks, gold investing, gold miners, hedge funds, high conviction investing, hub-hedge, John Paulson, macro investing, Madrigal Pharmaceuticals, Perpetua Resources, portfolio analysis
Investor hiker climbing a brain-shaped Acadia National Park trail marked by biotech milestones, symbolizing ACADIA Pharmaceuticals’ growth potential.

ACADIA Pharmaceuticals: Biotech Powerhouse Baker Bros Still Believes. Should You Buy In?

Biotech heavyweight Baker Bros still owns over 25% of ACADIA Pharmaceuticals (ACAD), and the stock is heating up. With expanding revenue, a rich CNS pipeline, and smart money backing it, is this the comeback story investors have been waiting for?

Read entire article

Tags: ACAD, ACADIA Pharmaceuticals, Baker Bros, Biotech Investing, Biotech Stocks, Funanc1al, Funanc1al Contrarian Picks, Funanc1al for Investors, Funanc1al Investing, Funanc1alBiotech, Funanc1alEdge, Funanc1alFinance, Funanc1alFun, Funanc1alHumor, Funanc1alInsiders, Funanc1alInvesting, Funanc1alMentalHealth, Funanc1alPharma, Funanc1alStocks, Growth Investing, Hedge Funds Investing, High-Conviction Investing, insider holdings, Parkinson’s disease, pharma pipeline, Rett Syndrome